losartan has been researched along with Erythrocytosis in 25 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan may be an effective agent for treatment of hyperuricemia and PTE in Han Chinese patients after kidney transplantation." | 9.14 | Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study. ( Chen, J; Cheng, M; Ding, X; Han, F; Le, Y; Xu, L; Zhang, L; Zhu, X, 2009) |
| "The aim of this prospective randomized study was to compare the safety and efficacy of enalapril (E) and losartan (L) in the treatment of posttransplantation erythrocytosis and the effect of the ACE genotype on response to therapy." | 9.09 | Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. ( Akkaya, V; Bozfakioğlu, S; Cine, N; Ismailoğlu, V; Sahin, S; Sever, MS; Türk, S; Yildiz, A, 2001) |
| "We assessed the clonogenic potential by colony-forming unit (CFU) assay of mononuclear cells isolated from PV JAK2 positive or JAK2 negative patients with erythrocytosis treated with enalaprilat or losartan." | 8.31 | Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera. ( Astori, G; Bernardi, M; Bozza, A; Catanzaro, D; Chieregato, K; Merlo, A, 2023) |
| "Losartan is a safe, effective long-term treatment for hypertension or posttransplant erythrocytosis (PTE) in renal transplant recipients." | 7.73 | Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. ( Cift, A; Dilek, K; Ersoy, A; Ersoy, C; Kahvecioglu, S, 2005) |
| "Losartan was withdrawn in 16 patients; hematocrit increased from 0." | 6.69 | Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. ( Barker, CV; Brantley, RR; Curtis, JJ; Gaston, RS; Julian, BA; Lee, JY; Prchal, JT; Stopka, T, 1998) |
| "Treatment with enalapril, 5 mg, reduced Hb levels more markedly than treatment with losartan, 50 mg, in patients with PTE." | 5.31 | Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis. ( Goh, J; Lam, CW; Li, PK; Lui, SF; Wang, AY; Yu, AW; Yu, LM, 2002) |
| "Erythrocytosis is a relatively common complication of renal transplantation." | 5.30 | Effects of losartan on the treatment of posttransplant erythrocytosis. ( Chahin, J; del Castillo, N; Gallego, E; García, J; Macía, M; Méndez, ML; Mora, C; Navarro, JF, 1998) |
| "Losartan may be an effective agent for treatment of hyperuricemia and PTE in Han Chinese patients after kidney transplantation." | 5.14 | Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study. ( Chen, J; Cheng, M; Ding, X; Han, F; Le, Y; Xu, L; Zhang, L; Zhu, X, 2009) |
| "We assessed the clonogenic potential by colony-forming unit (CFU) assay of mononuclear cells isolated from PV JAK2 positive or JAK2 negative patients with erythrocytosis treated with enalaprilat or losartan." | 4.31 | Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera. ( Astori, G; Bernardi, M; Bozza, A; Catanzaro, D; Chieregato, K; Merlo, A, 2023) |
| "Losartan is a safe, effective long-term treatment for hypertension or posttransplant erythrocytosis (PTE) in renal transplant recipients." | 3.73 | Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. ( Cift, A; Dilek, K; Ersoy, A; Ersoy, C; Kahvecioglu, S, 2005) |
| "ACE-inhibitors (lisinopril) or alternatively the use of angiotensin II receptor antagonists, like Losartan, at low doses, is an effective and safe treatment for patients developing post-transplantation erythrocytosis (PTE)." | 3.71 | [Treatment of post kidney transplantation erythrocytosis (PTE) with ACE inhibitors]. ( Cappello, D; Francesco, L; Morale, W; Puliatti, C; Puliatti, D; Valvo, C; Veroux, M; Veroux, P, 2002) |
| "Losartan was withdrawn in 16 patients; hematocrit increased from 0." | 2.69 | Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. ( Barker, CV; Brantley, RR; Curtis, JJ; Gaston, RS; Julian, BA; Lee, JY; Prchal, JT; Stopka, T, 1998) |
| "Treatment with enalapril, 5 mg, reduced Hb levels more markedly than treatment with losartan, 50 mg, in patients with PTE." | 1.31 | Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis. ( Goh, J; Lam, CW; Li, PK; Lui, SF; Wang, AY; Yu, AW; Yu, LM, 2002) |
| "Erythrocytosis is a relatively common complication of renal transplantation." | 1.30 | Effects of losartan on the treatment of posttransplant erythrocytosis. ( Chahin, J; del Castillo, N; Gallego, E; García, J; Macía, M; Méndez, ML; Mora, C; Navarro, JF, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (48.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 1 (4.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bozza, A | 1 |
| Bernardi, M | 1 |
| Catanzaro, D | 1 |
| Chieregato, K | 1 |
| Merlo, A | 1 |
| Astori, G | 1 |
| Vishnu, P | 1 |
| Moreno Vanegas, Y | 1 |
| Wadei, HM | 1 |
| Rivera, CE | 1 |
| Nouri-Majalan, N | 1 |
| Ghafari, A | 1 |
| Moghaddasi, S | 1 |
| Zhu, X | 1 |
| Chen, J | 1 |
| Han, F | 1 |
| Cheng, M | 1 |
| Xu, L | 1 |
| Zhang, L | 1 |
| Ding, X | 1 |
| Le, Y | 1 |
| Stoll, ML | 1 |
| Gauthier, BG | 1 |
| Vergara, M | 1 |
| Ramek, J | 1 |
| Frank, R | 1 |
| Trachtman, H | 1 |
| Ersoy, A | 1 |
| Kahvecioglu, S | 1 |
| Ersoy, C | 1 |
| Cift, A | 1 |
| Dilek, K | 1 |
| Midtvedt, K | 1 |
| Stokke, ES | 1 |
| Hartmann, A | 1 |
| Conlon, PJ | 1 |
| Smith, SR | 1 |
| Butterly, DW | 1 |
| Brennan, DC | 1 |
| Altun, B | 1 |
| Arici, M | 1 |
| Yasavul, U | 1 |
| Turgan, C | 1 |
| Cağlar, S | 1 |
| Ducloux, D | 1 |
| Fournier, V | 1 |
| Bresson-Vautrin, C | 1 |
| Chalopin, JM | 1 |
| Klaassen, RJ | 1 |
| van Gelder, T | 1 |
| Rischen-Vos, J | 1 |
| Deinum, J | 1 |
| Man in't Veld, AJ | 1 |
| Weimar, W | 1 |
| Navarro, JF | 2 |
| Macía, M | 2 |
| García, J | 2 |
| Julian, BA | 1 |
| Brantley, RR | 1 |
| Barker, CV | 1 |
| Stopka, T | 1 |
| Gaston, RS | 1 |
| Curtis, JJ | 1 |
| Lee, JY | 1 |
| Prchal, JT | 1 |
| Mora, C | 1 |
| Chahin, J | 1 |
| Gallego, E | 1 |
| Méndez, ML | 1 |
| del Castillo, N | 1 |
| Hortal, L | 1 |
| Fernández, A | 1 |
| Vega, N | 1 |
| Rodríguez, JC | 1 |
| Losada, A | 1 |
| Lorenzo, M | 1 |
| Plaza, C | 1 |
| Palop, L | 1 |
| Tsang, WK | 1 |
| Tong, KL | 1 |
| Chan, HW | 1 |
| Iñigo, P | 1 |
| Torregrosa, JV | 1 |
| Campistol, JM | 1 |
| Oppenheimer, F | 1 |
| Cachat, F | 1 |
| Guignard, JP | 1 |
| Duclos, J | 1 |
| Celik, A | 1 |
| Ok, E | 1 |
| Unsal, A | 1 |
| Töz, H | 1 |
| Atabay, G | 1 |
| Vlahakos, DV | 1 |
| Marathias, KP | 1 |
| Kosmas, EN | 1 |
| Yildiz, A | 1 |
| Cine, N | 1 |
| Akkaya, V | 1 |
| Sahin, S | 1 |
| Ismailoğlu, V | 1 |
| Türk, S | 1 |
| Bozfakioğlu, S | 1 |
| Sever, MS | 1 |
| Wang, AY | 1 |
| Yu, AW | 1 |
| Lam, CW | 1 |
| Yu, LM | 1 |
| Li, PK | 1 |
| Goh, J | 1 |
| Lui, SF | 1 |
| Morale, W | 1 |
| Puliatti, C | 1 |
| Veroux, P | 1 |
| Veroux, M | 1 |
| Valvo, C | 1 |
| Cappello, D | 1 |
| Puliatti, D | 1 |
| Francesco, L | 1 |
| Otero Glz, A | 1 |
| Pérez Melón, C | 1 |
| Armada, E | 1 |
| Gayoso, P | 1 |
8 trials available for losartan and Erythrocytosis
| Article | Year |
|---|---|
Effect of angiotensin II type-1 receptor blockers on stable allograft kidneys: prospective randomized study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Cholesterol, HDL; Creatinine; Female; Humans; Kidney | 2009 |
Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Case-Control Studies | 2009 |
Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis.
Topics: Angiotensin Receptor Antagonists; Erythropoietin; Female; Hematocrit; Humans; Kidney Transplantation | 1998 |
Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Erythrocyte Count; Erythropoietin; Hematocrit; Humans; Kid | 1998 |
Blockade of angiotensin II AT 1 receptor reduces hematocrit in patients with posttransplant erythrocytosis.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Female; Hematocrit | 1998 |
Treatment with losartan in kidney transplant recipients with posttransplant erythrocytosis.
Topics: Antihypertensive Agents; Follow-Up Studies; Hematocrit; Humans; Kidney Transplantation; Losartan; Mi | 1999 |
Comparison of enalapril and losartan in the treatment of posttransplant erythrocytosis.
Topics: Antihypertensive Agents; Enalapril; Female; Humans; Kidney Failure, Chronic; Kidney Transplantation; | 2000 |
Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Female; Genotype; Hemoglobins; Humans; K | 2001 |
17 other studies available for losartan and Erythrocytosis
| Article | Year |
|---|---|
Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera.
Topics: Enalaprilat; Erythrocytes; Humans; Losartan; Polycythemia; Polycythemia Vera | 2023 |
Post-transplant erythrocytosis refractory to ACE inhibitors and angiotensin receptor blockers.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Hematocrit; Hum | 2018 |
Efficacy of losartan in the treatment of erythrocytosis in a young adult with CRF.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Humans; | 2004 |
Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis.
Topics: Adult; Anemia; Antihypertensive Agents; Body Mass Index; Calcium Channel Blockers; Creatinine; Eryth | 2005 |
Successful long-term treatment of post-transplant erythrocytosis with losartan.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Erythropoietin | 1996 |
Losartan in post-transplant erythrocytosis.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 1996 |
Role of erythropoietin in pathogenesis of post transplant erythrocytosis (PTE) and mechanism of losartan's efficiency.
Topics: Antihypertensive Agents; Biphenyl Compounds; Erythropoietin; Humans; Imidazoles; Kidney Transplantat | 1997 |
Treatment of posttransplant erythrocytosis with losartan.
Topics: Adult; Antihypertensive Agents; Biphenyl Compounds; Female; Humans; Imidazoles; Kidney Transplantati | 1997 |
Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Erythrocyte Count; Hematocrit; Humans; Imidazo | 1997 |
Losartan for therapy of posttransplant erythrocytosis.
Topics: Adult; Angiotensin Receptor Antagonists; Humans; Kidney Transplantation; Losartan; Male; Polycythemi | 1997 |
Effects of losartan on the treatment of posttransplant erythrocytosis.
Topics: Adult; Angiotensin II; Humans; Kidney Transplantation; Losartan; Male; Polycythemia | 1998 |
Successful treatment of post-renal transplant erythrocytosis with losartan.
Topics: Adolescent; Female; Humans; Kidney Transplantation; Losartan; Polycythemia | 1999 |
[Erythrocytosis post kidney transplantation and its pharmacological treatment: angiotensin converting enzyme inhibitors or angiotensin receptor blockers in a case].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Humans; Kidney Transplantation; Losartan | 2000 |
Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis.
Topics: Female; Hematocrit; Humans; Losartan; Lung Diseases, Obstructive; Male; Middle Aged; Polycythemia; R | 2001 |
Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Enalapril; Erythropoietin; | 2002 |
[Treatment of post kidney transplantation erythrocytosis (PTE) with ACE inhibitors].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cyclosporine; Drug Evalu | 2002 |
[Uricemia-lowering activity of losartan in kidney transplantation].
Topics: Adult; Cyclosporine; Drug Evaluation; Erythroid Precursor Cells; Erythropoietin; Humans; Immunosuppr | 2002 |